OXB, a global quality and innovation-led cell and gene therapy CDMO, has entered into a licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), an Australian contract development and manufacturing organisation (CDMO) and the country’s first commercial manufacturing facility of its kind.
Further to the non-binding terms sheet signed in October 2025, this agreement provides VVMF with a worldwide, non-exclusive licence to OXB’s proprietary inAAVate™ platform know-how and intellectual property, with an option to extend the licence to its proprietary LentiVector™ platform. In return, OXB will receive a low single-digit million licence fee and is eligible for future payments related to the use of its platforms.
This five-year licence underpins the strategic collaboration between OXB and VVMF, enabling VVMF to accelerate its operational and commercial readiness to provide advanced viral vector technologies to customers, capturing global demand with a particular focus on the fast-growing APAC region, and positioning Australia as a regional hub for high-quality cell and gene therapy manufacturing.
By collaborating with VVMF, OXB is extending the global reach of its platforms, reinforcing its position as a trusted provider of viral vector development and manufacturing services. The agreement highlights the scalability and reliability of OXB’s platforms and technologies and reflects growing international recognition of its expertise.
